← All trials
NCT04415086
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2020
- Primary completion
- Apr 20, 2022
- Completion date
- May 22, 2022
- First posted
- Jun 3, 2020
- Last posted
- Jun 3, 2020
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Sao PauloLead sponsor
- University of Sao PauloCollaborator
- University of Sao PauloOverall official - principal investigator
- Albert Einstein Israelite HospitalCollaborator
- Hospital Sirio-LibanesCollaborator
- Hospital de Clínicas, Faculdade de Medicina Universidade Estadual de CampinasCollaborator
- Ministério da Ciência, Tecnologia, Inovações e ComunicaçõesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.